Vivanza Biosciences share price
You have to be logged in to add this to Watchlist.- ₹2.12(1.92%)May 12, 2025 15:57:56 PM IST
- NSE
- BSE
- Vol : 30.73K (NSE + BSE)Last 20 day avg : 54.96 K
Vivanza Biosciences is trading 1.92% upper at Rs 2.12 as compared to its last closing price. Vivanza Biosciences has been trading in the price range of 2.15 & 2.01. Vivanza Biosciences has given -38.01% in this year & -2.75% in the last 5 days. The company posted a net profit of 0.04 Crores in its last quarter.Listed peers of Vivanza Biosciences include Cian Healthcare (1.72%), Evoq Remedies (-%), Vivanza Biosciences (1.92%).The Mutual Fund holding in Vivanza Biosciences was at -% in . The MF holding has - from the last quarter. The FII holding in Vivanza Biosciences was at -% in . The FII holding has - from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on May 13, 2025, 01:37 AM UTC
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- P/BLower than historical values1.83The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values0.00Price-to-earnings ratio based on trailing 12-month earnings
- BetaHigh volatility1.17Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To Equity-The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable
The company's revenue fell during December quarter by 77.13% from Rs 6.56 crore to Rs 1.50 crore, year-on-year- The company's profit declined by 78.93% year-on-year during the December quarter, dropping from Rs 0.21 crore to Rs 0.04 crore
- Earnings are insufficient to cover the interest expenses on outstanding debt
- R1
- 2.38
- R2
- 2.52
- R3
- 2.71
- S1
- 2.05
- S2
- 1.86
- S3
- 1.72
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Cian Healthcare | Neutral | 3.54 | 1.72 | 8.85 | 35.17 | 0.15 | - | 47.62 |
| Evoq Remedies | Neutral | 3.49 | - | 8.69 | 87.25 | 0.2 | - | - |
| Vivanza Biosciences | Bearish | 2.12 | 1.92 | 8.48 | 14.86 | 1.79 | - | 57.82 |
| Ortin Global | Bearish | 10.70 | -0.83 | 8.70 | - | 2.94 | - | 63.82 |
| Shamrock Industrial | Bullish | 15.00 | - | 8.14 | - | 4.71 | - | - |
- Promoter(s) does not have a high stake in the company
- Promoter(s) have decreased the stake in the company in last 12 months
- FIIs are not invested in this company
- Mutual Funds are not invested in this company.
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-05-12 | Audited Results |
| 2025-01-31 | Quarterly Results & Others |
| 2024-10-17 | Quarterly Results |
| 2024-08-08 | Quarterly Results |
| 2024-07-05 | Others |
- IndustryBiotechnology & Drugs
- ISININE984E01035
- BSE Code530057
- NSE Code
Vivanza Biosciences is trading at 2.12 as on Mon May 12 2025 10:27:56. This is 1.92% upper as compared to its previous closing price of 2.08.
The market capitalization of Vivanza Biosciences is 8.48 Cr as on Mon May 12 2025 10:27:56.
The 52 wk high for Vivanza Biosciences is 7.80 whereas the 52 wk low is 1.90
Vivanza Biosciences can be analyzed on the following key metrics -
- TTM P/E:
- Sector P/E: -
- Dividend Yield: 0.00%
- D/E ratio: -
Vivanza Biosciences reported a net profit of 0.55 Cr in 2024.